17 Nov 2026

Isomorphic Labs unlocks a £3.8bn Series C round led by Greenoaks and Sequoia Capital to design new medicines with AI

Isomorphic Labs is an AI company focused on designing and developing new medicines. It is building a drug design engine, IsoDDE, made up of foundational simulation AI models that work across multiple therapeutic areas and drug modalities.

Isomorphic Labs, an AI company focused on designing and developing new medicines, has raised £3.8 billion in an oversubscribed Series C round. The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and several other new investors, with continued significant investment from Alphabet. All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Isomorphic is scaling its proprietary drug design engine, IsoDDE, and a pipeline of therapeutic candidates designed with AI. IsoDDE unifies a suite of foundational simulation AI models that work across multiple therapeutic areas and drug modalities, and explores chemical spaces to design, refine and deliver molecules with optimal drug-like properties. The company combines these models with proprietary agents that navigate and reason over complex biological systems.

Isomorphic reports positive preclinical results, both for internal programmes in oncology and immunology and with partners, setting the stage for clinical entry. The company was founded in 2021 and is advancing its drug design portfolio through partnered programmes and wholly owned internal programmes.

The company will continue to mature IsoDDE and expand into new biology with more advanced models. It is creating a partner ecosystem to advance the understanding of mechanistic disease biology and building global infrastructure for AI-led bioengineering. Proceeds will also support its build of AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials. Isomorphic is led by CEO Demis Hassabis and President Max Jaderberg, is headquartered in London and has offices in Cambridge, Massachusetts and Lausanne, Switzerland.

When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI. Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.

Demis Hassabis, Co-founder & CEO

Every week we are making repeatable scientific advancements enabled by our models. These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery. Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades. We are translating our discoveries directly into potential life-changing medicines, built on the infrastructure we are establishing for the future of bioengineering with this investor backing.

Max Jaderberg, President

Discovering and developing new medicines is an optimization challenge of almost infinite scale. Isomorphic is transforming that journey, building deep learning systems that can predict complex biological behaviors with remarkable accuracy and systematically map the path to new medicines. We believe Demis, Max, and the Isomorphic team are building the future of AI-led drug discovery and we are proud to partner with them on this essential mission.

Neil Mehta, Founding Partner at Greenoaks

Isomorphic Labs is building foundational technology for the future of medicine. It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co-lead this round and help further scientific discovery in medicine.

Konstantine Buhler, Partner at Sequoia Capital
Powered by
NatWestSageHarmonicNovus

Similar articles